Business Context and Reporting Period
This Form 6-K filing by AC Immune SA reports the results of the Annual General Meeting of Shareholders held on June 24, 2022. The filing covers shareholder approvals regarding the 2021 financial year, including financial statements, compensation reports, and governance matters.
Key Financial Metrics
The filing provides specific data regarding the company's accumulated losses and approved compensation budgets, but does not detail revenue, cash flow, or margins for the current period.
- 2021 Net Loss: KCHF 75,204 (CHF 75,204,000).
- Accumulated Losses (Post-2021): KCHF 195,179 (CHF 195,179,000), resulting from the addition of the 2021 net loss to the prior balance of KCHF 119,975.
- Approved Board Compensation (July 2022 - June 2023): Maximum CHF 1,242K.
- Approved Executive Committee Compensation:
- Non-performance cash (July 2022 - Dec 2022): CHF 1,498K.
- Variable cash (2022): CHF 1,158K.
- Equity grants (July 2022 - Dec 2022): CHF 1,839K.
- Total maximum (Jan 2023 - Dec 2023): CHF 7,895K.
Note: The filing text does not provide clear values for revenue, operating profit, cash flow, debt levels, or liquidity ratios.
Material Changes and Governance Actions
Shareholders approved several material changes to the company's capital structure and governance:
- Capital Authorization: Approved the issuance of up to 20,000,000 new registered common shares (CHF 0.02 nominal value) until June 24, 2024.
- Conditional Capital for Debt: Increased conditional capital for bonds/debt instruments to allow issuance of 5,000,000 shares (max CHF 100,000).
- Conditional Capital for Employees: Increased conditional capital for employee benefit plans to allow issuance of 4,800,000 shares (max CHF 96,000).
- Board Re-elections: Re-elected Douglas Williams (Chairman) and eight other directors, including Carl June and Werner Lanthaler, until the 2023 AGM.
- Auditor Re-election: Re-elected PricewaterhouseCoopers SA for a one-year term.
Outlook, Risks, and Management Commentary
The filing confirms shareholder endorsement of the 2021 Compensation Report and the discharge of the Board and Executive Committee for 2021 activities. The Management presentation to shareholders is attached as an exhibit but is not summarized in the text of this filing. No specific forward-looking guidance, risk factors, or unusual items are detailed within the body of this Form 6-K.
Investor Verification Checklist
- Verify the impact of the new authorized share capital (20,000,000 shares) on potential dilution.
- Review the attached 2021 IFRS Consolidated Financial Statements (Exhibit 99.1) for detailed revenue and cash flow data not present in this summary.
- Confirm the specific terms of the conditional capital increases for debt and employee plans in the amended Articles of Association (Exhibit 99.3).
- Assess the company's liquidity position given the accumulated losses of KCHF 195,179.